Sun Pharma receives DCGI approval to initiate clinical trail with Nafamostat Mesilate in Covid-19 patients
Sun Pharmaceuticals Industries has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan
for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 29 2020 | 5:46 PM IST